Sacituzumab Govitecan Combo for Lung Cancer
(EVOKE-02 Trial)
Trial Summary
What is the purpose of this trial?
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, you cannot have received systemic anticancer treatment in the past 6 months, and you should not be on chronic systemic steroid therapy.
What data supports the effectiveness of the drug Sacituzumab Govitecan Combo for Lung Cancer?
Research shows that combining pembrolizumab (an immune therapy drug) with platinum-based chemotherapy, like carboplatin or cisplatin, improves outcomes in advanced non-small cell lung cancer compared to chemotherapy alone. This suggests that adding Sacituzumab Govitecan to a similar combination might also be effective.12345
Is the Sacituzumab Govitecan Combo for Lung Cancer generally safe in humans?
The combination of pembrolizumab with carboplatin and other drugs has been studied for lung cancer, showing that while it can improve survival, it also increases the risk of serious side effects. These side effects can include severe adverse events, which are more common when additional drugs like atezolizumab are added to the treatment.16789
What makes the Sacituzumab Govitecan combo drug unique for lung cancer?
The Sacituzumab Govitecan combo is unique because it combines an antibody-drug conjugate (Sacituzumab Govitecan) with traditional chemotherapy agents (Carboplatin, Cisplatin) and an immunotherapy drug (Pembrolizumab), potentially offering a novel approach by targeting cancer cells directly while also boosting the immune system to fight lung cancer.12101112
Research Team
Gilead Study Director
Principal Investigator
Gilead Sciences
Eligibility Criteria
This trial is for adults with advanced or metastatic non-small-cell lung cancer (NSCLC) who haven't had systemic treatment for it. They should have a good performance status, meaning they can carry out daily activities with little or no assistance. Their blood counts and liver function need to be within certain ranges, and their disease must be measurable on scans.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Safety Run-in
Participants receive sacituzumab govitecan at de-escalating dose levels with pembrolizumab and carboplatin or cisplatin to determine the recommended phase 2 dose
Treatment
Participants receive sacituzumab govitecan at the recommended phase 2 dose with pembrolizumab and a platinum agent (carboplatin or cisplatin) based on cohort assignment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Carboplatin
- Cisplatin
- Pembrolizumab
- Sacituzumab Govitecan-hziy (SG)
Carboplatin is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Head and neck cancer
- Brain cancer
- Ovarian cancer
- Small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Gilead Sciences
Lead Sponsor
Daniel O'Day
Gilead Sciences
Chief Executive Officer since 2019
MBA from Columbia University
Dietmar Berger
Gilead Sciences
Chief Medical Officer
MD and PhD from Albert-Ludwigs University School of Medicine
Merck Sharp & Dohme LLC
Industry Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University